New stem cell filter could cut transplant complications in blood cancer patients

NCT ID NCT06047886

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new automated method (CliniMACS Prodigy) to select CD34 stem cells for patients with blood cancers who need a stem cell boost or second transplant. The goal is to reduce the risk of severe graft-versus-host disease (GVHD) while improving blood cell recovery. About 50 participants with conditions like AML, ALL, or MDS will be enrolled. The approach aims to make the cell-processing procedure simpler and safer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia chronic myelogenous leukemia, BCR-ABL1 positive hematopoietic and lymphoid system neoplasm lymphoid neoplasm myelodysplastic syndrome Myelodysplastic Syndromes primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • University of Alabama at Birmingham

    RECRUITING

    Birmingham, Alabama, 35294-3300, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••